| Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease NR West, AN Hegazy, BMJ Owens, SJ Bullers, B Linggi, S Buonocore, ... Nature medicine 23 (5), 579-589, 2017 | 673 | 2017 |
| Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer NR West, K Milne, PT Truong, N Macpherson, BH Nelson, PH Watson Breast cancer research 13, 1-13, 2011 | 438 | 2011 |
| Emerging cytokine networks in colorectal cancer NR West, S McCuaig, F Franchini, F Powrie Nature Reviews Immunology 15 (10), 615-629, 2015 | 383 | 2015 |
| Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer NR West, SE Kost, SD Martin, K Milne, RJ Deleeuw, BH Nelson, ... British journal of cancer 108 (1), 155-162, 2013 | 306 | 2013 |
| Circulating and tissue-resident CD4+ T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation AN Hegazy, NR West, MJT Stubbington, E Wendt, KIM Suijker, A Datsi, ... Gastroenterology 153 (5), 1320-1337. e16, 2017 | 294 | 2017 |
| ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation C Pearson, EE Thornton, B McKenzie, AL Schaupp, N Huskens, T Griseri, ... eLife 5, e10066, 2016 | 208 | 2016 |
| Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer NR West, JI Murray, PH Watson Oncogene 33 (12), 1485-1494, 2014 | 114 | 2014 |
| Coordination of immune-stroma crosstalk by IL-6 family cytokines NR West Frontiers in immunology 10, 457179, 2019 | 103 | 2019 |
| S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer NR West, PH Watson Oncogene 29 (14), 2083-2092, 2010 | 95 | 2010 |
| Oncostatin M suppresses oestrogen receptor-a expression and is associated with poor outcome in human breast cancer NR West, LC Murphy, PH Watson Endocr Relat Cancer 19 (2), 181-195, 2012 | 92 | 2012 |
| Immunotherapy not working? Check your microbiota NR West, F Powrie Cancer cell 28 (6), 687-689, 2015 | 64 | 2015 |
| Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I–driven CD8+ T cell response K Stockenhuber, AN Hegazy, NR West, NE Ilott, A Stockenhuber, ... Journal of Experimental Medicine 215 (8), 1987-1998, 2018 | 62 | 2018 |
| The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer JE Spowart, KN Townsend, H Huwait, S Eshragh, NR West, JN Ries, ... The Journal of pathology 228 (4), 437-447, 2012 | 61 | 2012 |
| The oncostatin M‐stromal cell axis in health and disease NR West, BMJ Owens, AN Hegazy Scandinavian Journal of Immunology 88 (3), e12694, 2018 | 57 | 2018 |
| Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12/Th1 axis G Ryzhakov, NR West, F Franchini, S Clare, NE Ilott, SN Sansom, ... Nature Communications 9 (1), 3797, 2018 | 55 | 2018 |
| Jab1 is a target of EGFR signaling in ERα-negative breast cancer J Wang, RO Barnes, NR West, M Olson, JE Chu, PH Watson Breast cancer research 10, 1-11, 2008 | 44 | 2008 |
| CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy MA Huseni, L Wang, JE Klementowicz, K Yuen, B Breart, C Orr, L Liu, Y Li, ... Cell Reports Medicine 4 (1), 2023 | 38 | 2023 |
| Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways R León, JI Murray, G Cragg, B Farnell, NR West, TCS Pace, PH Watson, ... Biochemistry 48 (44), 10591-10600, 2009 | 34 | 2009 |
| Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma KN Townsend, JE Spowart, H Huwait, S Eshragh, NR West, MA Elrick, ... PloS one 8 (12), e82406, 2013 | 31 | 2013 |
| The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer S McCuaig, D Barras, EH Mann, M Friedrich, SJ Bullers, A Janney, ... Clinical Cancer Research 26 (16), 4313-4325, 2020 | 30 | 2020 |
Brad H NelsonDirector, Deeley Research Centre, BC Cancer AgencyVerified email at bccancer.bc.ca
